AbbVie Inc. Vyalev revenue
Vyalev revenue at AbbVie Inc. came to $286.0M for the quarter to 30 Sep 2026, up 107.2% from a year earlier.
As AbbVie Inc. reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.
By quarter
| Period ending | Vyalev revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $286.0M | up 107.2% | 30 Oct 2026 |
| 30 Jun 2026 | $256.0M | up 161.2% | 31 Jul 2026 |
| 31 Mar 2026 | $201.0M | up 219.0% | 29 Apr 2026 |
| 31 Dec 2025 | $183.0M | — | 4 Feb 2026 |
| 30 Sep 2025 | $138.0M | — | 31 Oct 2025 |
| 30 Jun 2025 | $98.0M | — | 31 Jul 2025 |
| 31 Mar 2025 | $63.0M | — | 25 Apr 2025 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of AbbVie Inc.: Skyrizi revenue · Rinvoq revenue · Botox Therapeutic revenue · Vraylar revenue · Venclexta revenue · Humira revenue · Botox Cosmetic revenue · Imbruvica revenue · Ubrelvy revenue · Qulipta revenue · Creon revenue · Mavyret revenue · Elahere revenue · Juvederm Collection revenue · Linzess/Constella revenue · Ozurdex revenue · Epkinly revenue · Lumigan/Ganfort revenue · Duodopa revenue · Alphagan/Combigan revenue · Immunology revenue · Neuroscience revenue · Oncology revenue · Aesthetics revenue · financial statements
Every KPI and segment of ABBV, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
